Indivior Pharmaceuticals, Inc. INDV

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

Indivior Pharmaceuticals, Inc. and its subsidiaries (together, "Indivior" or the "Company") is the market leader in long-acting injectable medications for opioid use disorder (OUD). Indivior is focused on delivering evidence-based pharmacotherapies for OUD and is committed to advancing the neurobiological understanding of OUD as a chronic, relapsing, but treatable brain disease. For more than 25 years, Indivior has led innovation in addiction medicine, developing differentiated therapeutic solutions that support long-term patient recovery, expand access to care, and drive sustainable value for patients, healthcare systems and stockholders.

Headquartered in the U.S. in Richmond, Virginia, Indivior and its portfolio of products is available primarily in the U.S. with additional products available in Canada, Australia, France, and Germany.

Last close 34.47 2026-10-23
Market cap $4.07B 2026-06-30 share count
52-week range 24.28 - 42.81

Valuation FY2025 figures against the last close

P/S3.3x
P/E21.0x
P/FCF—
EV/EBITDA15.4x
Dividend yield—
Diluted EPS1.64

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2014
Revenue $1.24B$1.19B$1.09B$901.0M———
Cost of revenue $246.0M$231.0M$174.0M$151.0M———
Gross profit $994.0M$957.0M$919.0M$749.0M———
SG&A $634.0M$612.0M$565.0M$469.0M———
Total operating expenses —$919.0M$1.07B$831.0M———
Operating income $262.0M$38.0M-$152.0M-$81.0M$213.0M——
Interest expense $45.0M$41.0M$35.0M$27.0M———
Pre-tax income $239.0M$20.0M-$145.0M-$89.0M———
Income tax $29.0M$13.0M$19.0M$44.0M———
Net income $210.0M$7.0M-$126.0M-$44.0M$205.0M——
EPS, basic 1.680.05-0.92-0.32———
EPS, diluted 1.640.05-0.92-0.32———
Shares, diluted (wtd. avg.) 128.0M133.0M137.0M139.0M———

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2014
Cash and equivalents $195.0M$319.0M$316.0M$774.0M$1.10B——
Short-term investments $0$1.0M$94.0M————
Receivables $253.0M$254.0M$254.0M————
Inventory $153.0M$167.0M$126.0M————
Total current assets $652.0M$827.0M$1.26B————
Property, plant and equipment $144.0M$100.0M$84.0M————
Goodwill $2.0M$2.0M$5.0M————
Total assets $1.20B$1.32B$1.76B$1.77B$1.83B——
Accounts payable $48.0M$63.0M$195.0M————
Short-term debt $29.0M$18.0M$3.0M————
Total current liabilities $914.0M$924.0M$1.28B————
Long-term debt $290.0M$315.0M$237.0M————
Total liabilities $1.30B$1.65B$1.94B————
Retained earnings -$243.0M-$443.0M-$288.0M———-$1.29B
Total equity -$98.0M-$337.0M-$184.0M-$15.0M$121.0M$82.0M—

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2014
Operating cash flow -$27.0M$36.0M-$300.0M-$4.0M———
Depreciation and amortisation $10.0M$16.0M$15.0M$16.0M———
Stock-based compensation $26.0M$24.0M$21.0M$16.0M———
Capital expenditure $66.0M$29.0M$8.0M$5.0M———
Investing cash flow -$66.0M$69.0M-$95.0M-$222.0M———
Financing cash flow -$30.0M-$102.0M-$64.0M-$101.0M———
Buybacks $11.0M$173.0M$33.0M$90.0M———

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001628280-26-012237.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -500M 0 500M 1B 1.5B Net income, FY2021: 205M Revenue, FY2022: 901M Gross profit, FY2022: 749M Net income, FY2022: -44M Revenue, FY2023: 1.1B Gross profit, FY2023: 919M Net income, FY2023: -126M Revenue, FY2024: 1.2B Gross profit, FY2024: 957M Net income, FY2024: 7M Revenue, FY2025: 1.2B Gross profit, FY2025: 994M Net income, FY2025: 210M FY2014 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2014FY2020FY2021FY2022FY2023FY2024FY2025
Revenue — — — $901.0M $1.09B $1.19B $1.24B
Gross profit — — — $749.0M $919.0M $957.0M $994.0M
Net income — — $205.0M -$44.0M -$126.0M $7.0M $210.0M

Recent filings and events

  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Regulation FD disclosure Item 7.01
  • Regulation FD disclosure Item 7.01
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Regulation FD disclosure Item 7.01
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01
  • Material agreement signed Item 1.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%